



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

| APRI (Common Stock) | |
|---------------------|------------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$1.04 |
| Change (%) | ▼ 2.15 (67.40%) |
| Volume | 18,848,779 |
| 52 Week High | \$3.49 |
| 52 Week Low | \$0.86 |
| Market Cap | \$15,824,138 |
| Rolling EPS | -0.93 |
| PE Ratio | 0 |
| Shares Outstanding | 15,215,517 |

Data as of 02/16/18 4:00 p.m. ET



Recent Headlines

02/16/18
[Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™](#)

11/02/17
[Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results](#)

10/26/17
[Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

| Filing Date | Form |
|-------------|----------|
| 02/16/18 | 8-K |
| 02/14/18 | SC 13G/A |
| 02/14/18 | SC 13G/A |
| 01/31/18 | SC 13D/A |

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.